12 results found.

Clostridium Difficile Colitis Clinical Trial using FMT; placebo

MemorialCare Health System - Recruiting 1 year to 21 years.
- A Randomized, Placebo-controlled Pilot Trial to Administer Fecal Microbial Therapy (Stool Transplant) or Placebo in Children Ages 8 to 18 With Recurrent C. Difficile Infection.
FMT; placebo

Clostridium Difficile Infection Clinical Trial using MK-3415; MK-6072; MK-3415A; Placebo; SOC

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I).
MK-3415; MK-6072; MK-3415A; Placebo; SOC

Clostridium Difficile Infection Clinical Trial using MK-6072; MK-3415A; Placebo; SOC

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II).
MK-6072; MK-3415A; Placebo; SOC

Clostridium Difficile Infection Clinical Trial using Fresh Human Biotherapy; Frozen-and-Thawed Human Biotherapy

McMaster University - Recruiting 18 years or older.
- A Prospective Randomized Multi-Centre Trial of Fresh vs. Frozen-and-Thawed Human Biotherapy (Fecal Transplant) for Recurrent Clostridium Difficile Infection.
Fresh Human Biotherapy; Frozen-and-Thawed Human Biotherapy

Clostridium Difficile Infection Clinical Trial using CB-183,315; oral vancomycin

Cubist Pharmaceuticals - Recruiting 18 years to 90 years.
- A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea.
CB-183,315; oral vancomycin

Clostridium Difficile Infection Clinical Trial using CB-183,315; oral vancomycin

Cubist Pharmaceuticals - Recruiting 18 years to 90 years.
- A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea.
CB-183,315; oral vancomycin

Clostridium Difficile Infection Clinical Trial using Human fecal matter

Englewood Hospital and Medical Center - Recruiting 18 years or older.
- Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI).
Human fecal matter

Clostridium Difficile Infection Clinical Trial using Clostridium difficile Toxoid Vaccine; 0.9% normal saline

Sanofi - Recruiting 40 years to 75 years.
- Safety and Immunogenicity of a Clostridium Difficile Toxoid Vaccine Administered to Healthy Adult Subjects Aged 40 to 75 Years in Japan.
Clostridium difficile Toxoid Vaccine; 0.9% normal saline

Clostridium Difficile Infection Clinical Trial using Rifaximin; Placebo

University of Nottingham - Recruiting 18 years or older.
- A Randomised Placebo Controlled Trial of 'Follow on' Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea.
Rifaximin; Placebo

Clostridium Difficile Infection Clinical Trial using C. difficile Toxoid Vaccine; Placebo: 0.9% normal saline

Sanofi - Recruiting 50 years or older.
- Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection.
C. difficile Toxoid Vaccine; Placebo: 0.9% normal saline

Clostridium Difficile Infection Clinical Trial using Fecal Microbiota Transplant

Massachusetts General Hospital - Recruiting 7 years to 90 years.
- Fecal Microbiota Transplant (FMT) for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum.
Fecal Microbiota Transplant

Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, or In Clinical Trial using Blood and stool sample

Boston Medical Center - Recruiting 18 years or older.
- Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients.
Blood and stool sample